metformin has been researched along with Myocardial Ischemia in 28 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin (Met) has a protective effect against cardiac ischemia and reperfusion (I/R) injury." | 8.31 | Metformin ameliorates ferroptosis in cardiac ischemia and reperfusion by reducing NOX4 expression via promoting AMPKα. ( Bai, Y; Chang, C; Guo, Z; Jiao, Y; Qi, Y; Wu, Z, 2023) |
| "Metformin-associated lactic acidosis (MALA) is one of the most important drug toxicities with a high morbidity and mortality rate." | 7.83 | Myocardial injury and acute renal failure associated with lactic acidosis due to suicide attempt with metformin. ( Berber, E; Ordu, O; Ozdemir, A; Ozen, B; Sertbas, M; Sertbas, Y, 2016) |
| "Metformin treatment in the context of metabolic syndrome and myocardial ischemia dramatically upregulates the insulin signaling pathway in chronically ischemic myocardium, which is at the crossroads of known metabolic and survival benefits of metformin." | 7.79 | Metformin alters the insulin signaling pathway in ischemic cardiac tissue in a swine model of metabolic syndrome. ( Chu, LM; Elmadhun, NY; Lassaletta, AD; Sellke, FW, 2013) |
| "In comparison with placebo (n = 17), metformin recipients (n = 16) showed significant reductions in weight and in homeostatic model assessment for insulin resistance (p < 0." | 5.12 | Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. ( Cobbe, SM; Ferrell, W; Greer, IA; Jadhav, S; Petrie, JR; Sattar, N, 2006) |
| "Metformin (Met) has a protective effect against cardiac ischemia and reperfusion (I/R) injury." | 4.31 | Metformin ameliorates ferroptosis in cardiac ischemia and reperfusion by reducing NOX4 expression via promoting AMPKα. ( Bai, Y; Chang, C; Guo, Z; Jiao, Y; Qi, Y; Wu, Z, 2023) |
| "Metformin-associated lactic acidosis (MALA) is one of the most important drug toxicities with a high morbidity and mortality rate." | 3.83 | Myocardial injury and acute renal failure associated with lactic acidosis due to suicide attempt with metformin. ( Berber, E; Ordu, O; Ozdemir, A; Ozen, B; Sertbas, M; Sertbas, Y, 2016) |
| "Although both vildagliptin and metformin improved insulin resistance and attenuate myocardial injury caused by I/R, combined drugs provided better outcomes than single therapy by reducing arrhythmia score and mortality rate." | 3.80 | Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. ( Apaijai, N; Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S, 2014) |
| "Metformin treatment in the context of metabolic syndrome and myocardial ischemia dramatically upregulates the insulin signaling pathway in chronically ischemic myocardium, which is at the crossroads of known metabolic and survival benefits of metformin." | 3.79 | Metformin alters the insulin signaling pathway in ischemic cardiac tissue in a swine model of metabolic syndrome. ( Chu, LM; Elmadhun, NY; Lassaletta, AD; Sellke, FW, 2013) |
| "Right atrial sections from four patient groups-non-diabetic, insulin-dependent diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus (NIDDM) receiving glibenclamide, and NIDDM receiving metformin-were subjected to one of the following protocols: aerobic control, simulated ischemia/reoxygenation, ischemic preconditioning before ischemia, and pharmacological preconditioning with alpha 1 agonist phenylephrine, adenosine, the mito-K(ATP) channel opener diazoxide, the protein kinase C (PKC) activator phorbol-12-myristate-13-acetate (PMA), or the p38 mitogen-activated protein kinase (p38MAPK) activator anisomycin." | 3.73 | Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. ( Fowler, A; Galiñanes, M; Hassouna, A; Loubani, M; Matata, BM; Standen, NB, 2006) |
| "Metformin has unique, intrinsic actions specifically at the level of terminal arterioles, which are completely independent of its antidiabetic effect." | 2.48 | Microvascular diseases: is a new era coming? ( Rapin, JR; Wiernsperger, N, 2012) |
| "In patients with type 2 diabetes mellitus, treatment with metformin is associated with a lower cardiovascular morbidity and mortality, compared with alternative glucose-lowering drugs." | 2.47 | The cardioprotective effects of metformin. ( de Boer, RA; El Messaoudi, S; Riksen, NP; Rongen, GA, 2011) |
| "A model that incorporates HbA1c and diabetes complications can serve as a useful clinical decision tool for selection of treatment options." | 1.40 | Second-line agents for glycemic control for type 2 diabetes: are newer agents better? ( Denton, BT; Mason, JE; McCoy, RG; Shah, ND; Smith, SA; Zhang, Y, 2014) |
| "Metformin was administered 60 min prior to induction of global ischemia, or in combination with a nitric oxide synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), at 5 min or 60 min prior to the ischemia." | 1.32 | Cardioprotection by metformin is abolished by a nitric oxide synthase inhibitor in ischemic rabbit hearts. ( Ishikawa, K; Kawabata, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (35.71) | 29.6817 |
| 2010's | 15 (53.57) | 24.3611 |
| 2020's | 3 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, Z | 1 |
| Bai, Y | 2 |
| Qi, Y | 1 |
| Chang, C | 1 |
| Jiao, Y | 1 |
| Guo, Z | 1 |
| Fei, Q | 1 |
| Ma, H | 1 |
| Zou, J | 1 |
| Wang, W | 1 |
| Zhu, L | 1 |
| Deng, H | 1 |
| Meng, M | 1 |
| Tan, S | 1 |
| Zhang, H | 1 |
| Xiao, X | 1 |
| Wang, N | 1 |
| Wang, K | 1 |
| Chen, Q | 1 |
| Lesnefsky, EJ | 1 |
| Lu, L | 1 |
| Ye, S | 1 |
| Scalzo, RL | 1 |
| Reusch, JEB | 1 |
| Greyson, CR | 1 |
| Schwartz, GG | 1 |
| Fadini, GP | 1 |
| Frison, V | 1 |
| Simioni, N | 1 |
| Lapolla, A | 1 |
| Gatti, A | 1 |
| Bossi, AC | 1 |
| Del Buono, A | 1 |
| Fornengo, P | 1 |
| Gottardo, L | 1 |
| Laudato, M | 1 |
| Perseghin, G | 1 |
| Bonora, E | 1 |
| Avogaro, A | 1 |
| Zhang, Y | 1 |
| McCoy, RG | 1 |
| Mason, JE | 1 |
| Smith, SA | 1 |
| Shah, ND | 1 |
| Denton, BT | 1 |
| Elmadhun, NY | 3 |
| Sabe, AA | 1 |
| Lassaletta, AD | 3 |
| Chu, LM | 3 |
| Sellke, FW | 3 |
| Apaijai, N | 1 |
| Chinda, K | 1 |
| Palee, S | 1 |
| Chattipakorn, S | 1 |
| Chattipakorn, N | 1 |
| Vrbíková, J | 1 |
| Sertbas, M | 1 |
| Sertbas, Y | 1 |
| Ordu, O | 1 |
| Berber, E | 1 |
| Ozen, B | 1 |
| Ozdemir, A | 1 |
| Biondi-Zoccai, G | 1 |
| Pinto, A | 1 |
| Versaci, F | 1 |
| Procaccini, E | 1 |
| Neri, G | 1 |
| Sesti, G | 1 |
| Uccioli, L | 1 |
| Vetere, M | 1 |
| Peruzzi, M | 1 |
| Nudi, F | 1 |
| Sauvé, M | 1 |
| Ban, K | 1 |
| Momen, MA | 1 |
| Zhou, YQ | 1 |
| Henkelman, RM | 1 |
| Husain, M | 1 |
| Drucker, DJ | 1 |
| Alonso-García, A | 1 |
| García-Soidán, FJ | 1 |
| Lisbona-Gil, A | 1 |
| El Messaoudi, S | 1 |
| Rongen, GA | 1 |
| de Boer, RA | 1 |
| Riksen, NP | 1 |
| Robich, MP | 1 |
| Feng, J | 1 |
| Burgess, TA | 1 |
| Laham, RJ | 1 |
| Sturek, M | 1 |
| Wiernsperger, N | 1 |
| Rapin, JR | 1 |
| Monami, M | 1 |
| Filippi, L | 1 |
| Ungar, A | 1 |
| Sgrilli, F | 1 |
| Antenore, A | 1 |
| Dicembrini, I | 1 |
| Bagnoli, P | 1 |
| Marchionni, N | 1 |
| Rotella, CM | 1 |
| Mannucci, E | 1 |
| Kawabata, H | 1 |
| Ishikawa, K | 1 |
| Johnson, JA | 1 |
| Majumdar, SR | 1 |
| Kola, B | 1 |
| Hubina, E | 1 |
| Tucci, SA | 1 |
| Kirkham, TC | 1 |
| Garcia, EA | 1 |
| Mitchell, SE | 1 |
| Williams, LM | 1 |
| Hawley, SA | 1 |
| Hardie, DG | 1 |
| Grossman, AB | 1 |
| Korbonits, M | 1 |
| Capano, M | 1 |
| Crompton, M | 1 |
| Hassouna, A | 1 |
| Loubani, M | 1 |
| Matata, BM | 1 |
| Fowler, A | 1 |
| Standen, NB | 1 |
| Galiñanes, M | 1 |
| Jadhav, S | 1 |
| Ferrell, W | 1 |
| Greer, IA | 1 |
| Petrie, JR | 1 |
| Cobbe, SM | 1 |
| Sattar, N | 1 |
| Bhamra, GS | 1 |
| Hausenloy, DJ | 1 |
| Davidson, SM | 1 |
| Carr, RD | 1 |
| Paiva, M | 1 |
| Wynne, AM | 1 |
| Mocanu, MM | 1 |
| Yellon, DM | 1 |
| Olsson, J | 1 |
| Lindberg, G | 1 |
| Gottsäter, M | 1 |
| Lindwall, K | 1 |
| Sjöstrand, A | 1 |
| Tisell, A | 1 |
| Melander, A | 1 |
| Greenfield, JR | 1 |
| Chisholm, DJ | 1 |
| Legtenberg, RJ | 1 |
| Houston, RJ | 1 |
| Oeseburg, B | 1 |
| Smits, P | 1 |
4 reviews available for metformin and Myocardial Ischemia
| Article | Year |
|---|---|
[Polycystic ovary syndrome].
Topics: Androgen Antagonists; Anovulation; Combined Modality Therapy; Contraceptives, Oral, Hormonal; Diabet | 2015 |
The cardioprotective effects of metformin.
Topics: Animals; Cardiotonic Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Cardiomyo | 2011 |
Microvascular diseases: is a new era coming?
Topics: Diabetic Angiopathies; Hemorheology; Humans; Metformin; Microcirculation; Microvessels; Myocardial I | 2012 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
2 trials available for metformin and Myocardial Ischemia
| Article | Year |
|---|---|
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Angina Pectoris; Double-Blind Method; Electrocardiography; Exercise Tolerance; Female; Humans | 2006 |
23 other studies available for metformin and Myocardial Ischemia
| Article | Year |
|---|---|
Metformin ameliorates ferroptosis in cardiac ischemia and reperfusion by reducing NOX4 expression via promoting AMPKα.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line; Ferroptosis; Iron; Ischemia; Metformin | 2023 |
Metformin protects against ischaemic myocardial injury by alleviating autophagy-ROS-NLRP3-mediated inflammatory response in macrophages.
Topics: Adenosine Triphosphate; Animals; Autophagy; DNA, Mitochondrial; Female; Hemodynamics; Hydrogen Perox | 2020 |
Metformin and myocardial ischemia and reperfusion injury: Moving toward "prime time" human use?
Topics: Humans; Metformin; Myocardial Ischemia; Myocardial Reperfusion Injury; Reperfusion Injury | 2021 |
Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs.
Topics: Adenosine Triphosphate; Administration, Intravenous; AMP-Activated Protein Kinases; Animals; Citrate | 2017 |
Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2019 |
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?
Topics: Amputation, Surgical; Blood Glucose; Coronary Artery Disease; Diabetes Complications; Diabetes Melli | 2014 |
Metformin mitigates apoptosis in ischemic myocardium.
Topics: Animals; Apoptosis; Cardiotonic Agents; Disease Models, Animal; Forkhead Transcription Factors; Hypo | 2014 |
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
Topics: Adamantane; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhi | 2014 |
Myocardial injury and acute renal failure associated with lactic acidosis due to suicide attempt with metformin.
Topics: Acidosis, Lactic; Acute Kidney Injury; Emergency Medical Services; Humans; Hypoglycemic Agents; Male | 2016 |
Comparative Impact of Hypoglycemic Agents on Severity and Extent of Myocardial Ischemia in Patients With Type 2 Diabetes Mellitus Undergoing Myocardial Perfusion Scintigraphy.
Topics: Aged; Chi-Square Distribution; Coronary Angiography; Databases, Factual; Diabetes Mellitus, Type 2; | 2016 |
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Topics: Animals; Cardiovascular System; Coronary Vessels; Diabetes Mellitus, Experimental; Dipeptidyl Peptid | 2010 |
[Treatment guidelines for hyperglycaemia in type 2 diabetes patients with stable chronic heart failure or ischemic cardiomyopathy without heart failure].
Topics: Acute Coronary Syndrome; Algorithms; Consensus; Contraindications; Diabetes Mellitus, Type 2; Drug T | 2010 |
Overfed Ossabaw swine with early stage metabolic syndrome have normal coronary collateral development in response to chronic ischemia.
Topics: Animals; Collateral Circulation; Coronary Vessels; Diet, High-Fat; Hemodynamics; Hypoglycemic Agents | 2012 |
Metformin alters the insulin signaling pathway in ischemic cardiac tissue in a swine model of metabolic syndrome.
Topics: AMP-Activated Protein Kinases; Animals; Coronary Circulation; Disease Models, Animal; Energy Metabol | 2013 |
Cardioprotection by metformin is abolished by a nitric oxide synthase inhibitor in ischemic rabbit hearts.
Topics: Animals; Cardiotonic Agents; Drug Interactions; Energy Metabolism; Enzyme Inhibitors; Hypoglycemic A | 2003 |
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Drug Interactions; Humans; Hypog | 2004 |
Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Cannabinoids; Dimerization; Dronabinol; Ghre | 2005 |
Bax translocates to mitochondria of heart cells during simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated protein kinases.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; bcl-2-Associated X Protein; Cell | 2006 |
Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium.
Topics: Adenosine; Adrenergic alpha-Agonists; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitu | 2006 |
Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening.
Topics: Animals; Chromones; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Dru | 2008 |
Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study.
Topics: Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemogl | 2000 |
Clinical trials and clinical practice--bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Diabetes Mell | 2000 |
Metformin improves cardiac functional recovery after ischemia in rats.
Topics: Animals; Cardiac Output; Hypoglycemic Agents; In Vitro Techniques; Male; Metformin; Myocardial Ische | 2002 |